Current therapeutic approaches to fungal infections in immunocompromised hematological patients

Blood Reviews

Volumn 24, Issue 2, 2010, Pages 51-61

  Pagano, Livio ^a   Caira, Morena ^a   Valentini, Caterina Giovanna ^a   Posteraro, Brunella ^a   Fianchi, Luana ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Hemopoietic stem cell transplantation; Leukemia; Moulds; Yeasts

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNGAL EXAMINATION; FUSARIOSIS; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION RISK; INVASIVE CANDIDIASIS; LABORATORY DIAGNOSIS; LIVER TOXICITY; MORTALITY; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIODIAGNOSIS; RISK FACTOR; SURVIVAL RATE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; RISK FACTORS;

EID: 77249109748     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.11.003     Document Type: Article

References (128)

1. Pagano L., Caira M., Candoni A., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91 (2006) 1068-1075
2. Nivoix Y., Velten M., Letscher-Bru V., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 47 (2008) 1176-1184
3. Pagano L., Caira M., Nosari A., et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Clin Infect Dis 45 (2007) 1161-1170
4. Kami M., Machida U., Okuzumi K., et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 117 (2002) 40-46
5. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
6. McNeil M.M., Nash S.L., Hajjeh R.A., et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33 (2001) 641-647
7. Jantunen E., Salonen J., and Juvonen E. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 73 (2004) 174-178
8. Pagano L., Antinori A., Ammassari A., et al. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Eur J Haematol 63 (1999) 77-85
9. Marr K.A., Seidel K., White T.C., and Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181 (2000) 309-316
10. Pagano L., Offidani M., Fianchi L., et al. Mucormycosis in hematologic patients. Haematologica 89 (2004) 207-214
11. Kontoyiannis D.P., Wessel V.C., Bodey G.P., and Rolston K.V. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 30 (2000) 851-856
12. Girmenia C., Pagano L., Corvatta L., Mele L., del Favero A., and Martino P. The epidemiology of fusariosis in patients with haematological diseases. Br J Haematol 111 (2000) 272-276
13. Girmenia C., Pagano L., Martino B., et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 43 (2005) 1818-1828
14. Caira M., Girmenia C., Valentini C.G., et al. Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. Haematologica 93 (2008) 104-110
15. Mahfouz T., and Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 4 (2003) 974-990
16. Hamadani M., Hofmeister C.C., Jansak B., et al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant 14 (2008) 783-789
17. Martin S.I., Marty F.M., Fiumara K., Treon S.P., Gribben J.G., and Baden L.R. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43 (2006) 16-24
18. Gerson S.L., Talbot G.H., Hurwitz S., Strom B.L., Lusk E.J., and Cassileth P.A. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100 (1984) 345-351
19. Ng T.T., Robson G.D., and Denning D.W. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140 (1994) 2475-2479
20. Bassetti M., Trecarichi E.M., Righi E., et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 58 (2007) 325-331
21. Donnelly J.P. Symptoms and diagnosis of nosocomial fungal infections-state-of-the-art. Eur J Med Res 7 (2002) 192-199
22. Singh N., and Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 18 (2005) 44-69
23. Almyroudis N.G., and Segal B.H. Prevention and treatment of invasive fungal diseases in neutropenic patients. Curr Opin Infect Dis 22 (2009) 385-393
24. Marr K.A., Laverdiere M., Gugel A., and Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40 (2005) 1762-1769
25. Adam O., Aupérin A., Wilquin F., Bourhis J.H., Gachot B., and Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 38 (2004) 917-920
26. Pfeiffer C.D., Fine J.P., and Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42 (2006) 1417-1427
27. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39 (2004) 199-205
28. Hachem R.Y., Kontoyiannis D.P., Chemaly R.F., Jiang Y., Reitzel R., and Raad I. Utility of galactomannan enzyme immunoassay and (1 → 3) beta-d-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 47 (2009) 129-133
29. White P.L., Perry M.D., and Barnes R.A. An update on the molecular diagnosis of invasive fungal disease. FEMS Microbiol Lett 296 (2009) 1-10
30. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46 (2008) 1813-1821
31. Suarez F., Lortholary O., Buland S., et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol 46 (2008) 3772-3777
32. Mengoli C., Cruciani M., Barnes R.A., Loeffler J., and Donnelly J.P. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 9 (2009) 89-96
33. White P.L., Archer A.E., and Barnes R.A. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol 43 (2005) 2181-2187
34. White P.L., Barton R., Guiver M., et al. A consensus on fungal polymerase chain reaction diagnosis? A United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. J Mol Diagn 8 (2006) 376-384
35. Romani L. Immunity to fungal infections. Nat Rev Immunol 4 (2004) 1-23
36. Potenza L., Barozzi P., Vallerini D., et al. Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in patients with pulmonary infiltrates. Leukemia 21 (2007) 578-582
37. Wah T.M., Moss H.A., Robertson R.J., and Barnard D.L. Pulmonary complications following bone marrow transplantation. Br J Radiol 76 (2003) 373-379
38. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19 (2001) 253-259
39. Caillot D., Latrabe V., Thiébaut A., et al. Computer tomography in pulmonary invasive aspergillosis in haematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol (2009) 10.1016/j.ejrad.2009.05.05
40. Lass-Florl G., Nachbaur D., Mayr A., et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 45 (2007) e101-e104
41. Mahfouz T., Miceli M.H., Saghafifar F., et al. 18F-Fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol 23 (2005) 7857-7863
42. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 327-360
43. Bow E.J., Laverdiere M., Lussier N., et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials. Cancer 94 (2002) 3230-3246
44. Cornely O.A., Ullmann A.J., and Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101 (2003) 3365-3372
45. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326 (1992) 845-851
46. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 171 (1995) 1545-1552
47. Glasmacher A., Prentice A., Gorschlüter M., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol 21 (2003) 4615-4626
48. Glasmacher A., Cornely O., Ullmann A.J., et al., Itraconazole Research Group of Germany. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 57 (2006) 317-325
49. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
50. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
51. De Pauw B.E., and Donnelly J.P. Prophylaxis and aspergillosis-has the principle been proven?. N Engl J Med 356 (2007) 409-411
52. Trifilio S.M., Bennett C.L., Yarnold P.R., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39 (2007) 425-429
53. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycoses in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191 (2005) 1350-1360
54. Wingard J.R., Carter S.L., Walsh T.J., et al. Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood 110 (2007) 55a abstract 163
55. Gergis U, Markey K, Greene J, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant doi:10.1038/bmt.2009.210.
56. Cordonnier C., Mohty M., Faucher C., et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 31 (2008) 135-141
57. Rijnders B.J., Cornelissen J.J., Slobbe L., et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 46 (2008) 1401-1408
58. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
59. Chou L.S., Lewis R.E., Ippoliti C., et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 27 (2007) 1644-1650
60. Cornely O.A., Böhme A., Reichert D., et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 61 (2008) 939-946
61. Vehreschild J.J., Sieniawski M., Reuter S., et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicr Ag 34 (2009) 446-450
62. Maertens J.A., Frere P., Lass-Florl C., Heinz W., and Cornely O.A. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer S5 (2007) 43-48
63. NCCN Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf.
64. Cornely O.A., Böhme A., Buchheidt D., et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94 1 (2009) 113-122
65. Girmenia C., Barosi G., Aversa F., et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 49 (2009) 1226-1236
66. Pizzo P.A., Robichaud K.J., Gill F.A., and Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 (1982) 101-111
67. Viscoli C., Castagnola E., Van Lint M.T., et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 32A (1996) 814-820
68. Prentice H.G., Hann I.M., Herbrecht R., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98 (1997) 711-718
69. Malik I.A., Moid I., Aziz Z., Khan S., and Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 105 (1998) 478-483
70. White M.H., Bowden R.A., Sandler E.S., et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27 (1998) 296-302
71. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340 (1999) 764-771
72. Winston D.J., Hathorn J.W., Schuster M.G., Schiller G.J., and Territo M.C. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108 (2000) 282-289
73. Wingard J.R., White M.H., Anaissie E., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31 (2000) 1155-1163
74. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135 (2001) 412-422
75. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002) 225-234
76. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
77. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 (2005) 1242-1250
78. Girmenia C., Micozzi A., Gentile G., et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol (2009) 10.1200/JCO.2009.21.803
79. Cordonnier C., Pautas C., Maury S., et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48 (2009) 1042-1051
80. Marchetti O., Cordonnier C., and Calandra T. Empirical antifungal therapy in neutropenic cancer patients with persistent fever. Eur J cancer S5 (2007) 32-42
81. Prentice AG, Glasmacher A, Hobson RP, et al. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. http://www.bcshguidelines.com/pdf/IFI_therapy.pdf.
82. Rex J.H., Bennet J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331 (1994) 1325-1330
83. Anaissie E.J., Vartivarian S.E., Abi-Said D., et al. Fluconazole versus amphotericin B in the treatment of hematogenus candidiasis: a matched cohort study. Am J Med 101 (1996) 170-176
84. Reboli A.C., Rotstein C., Pappas P.G., et al., Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472-2482
85. Mora-Duarte J., Betts R., Rotstein C., et al., Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
86. Pappas P.G., Rotstein C.M., Betts R.F., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
87. Kuse E.R., Chetchotisakd P., da Cunha C.A., et al., Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007) 1519-1527
88. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 (2005) 1435-1442
89. Ostrosky-Zeichner L., Oude Lashof A.M., Kullberg B.J., and Rex J.H. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22 (2003) 651-655
90. Arrieta AC, Shea K, Dhar V, et al. Safety of liposomal amphotericin as a once-weekly antifungal prophylactic regimen in very low birth-weight premature infants. P1035, 17th ECCMID 31 March-3 April 2007, Munich.
91. Pagano L., Fianchi L., Fanci R., et al. Caspofungin for the treatment of candidaemia in patients with haematological malignancies. Clin Microbiol Infect (2009) 10.1111/j.1469-0691.2009.02832.x
92. Betts R.F., Nucci M., Talwar D., et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48 (2009) 676-684
93. Safdar A., Hanna H.A., Boktour M., et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 101 (2004) 2859-2865
94. Safdar A., Rodriguez G.H., Lichtiger B., et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 106 (2006) 2664-2671
95. Herbrecht R., Fluckiger U., Gachot B., Ribaud P., Thiebaut A., and Cordonnier P. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer 5 Suppl. 2 (2007) 49-59
96. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 503-535
97. Oppenheim B.A., Herbrecht R., and Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 21 (1995) 1145-1153
98. Walsh T.J., Hiemenz J.W., Seibel N.L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26 (1998) 1383-1396
99. Cornely O.A., Maertens J., Bresnik M., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44 10 (2007) 1289-1297
100. Ellis M., Spence D., de Pauw B., et al. An EORTC international multicenter randomized trial comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27 (1998) 1406-1412
101. Bowden R., Chandrasekar P., White M.H., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35 (2002) 359-366
102. Denning D.W., Lee J.Y., Hostetler J.S., et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97 (1994) 135-144
103. Caillot D., Bassaris H., McGeer A., et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33 (2001) e83-e90
104. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
105. Upton A., Kirby K.A., Carpenter P., Boeckh M., and Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44 (2007) 531-540
106. Pagano L., Caira M., Candoni A., et al. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica (2009) 10.3324/haematol.2009.01205
107. Candoni A., Mestroni R., Damiani D., et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 75 (2005) 227-233
108. Viscoli C., Herbrecht R., Akan H., et al. Caspofungin as a first-line therapy of invasive aspergillosis in haematological patients. A study of the EORTC Diseases Group. J Antimicrob Chemother (2009) 10.1093/jac/dkp35
109. Maertens J., Raad I., Petrikkos G., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
110. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
111. Aliff T.B., Maslak P.G., Jurcic J.G., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97 (2003) 1025-1032
112. Kontoyiannis D.P., Hachem R., Lewis R.E., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 (2003) 292-299
113. Maertens J., Glasmacher A., Herbrecht R., et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107 (2006) 2888-2897
114. Denning D.W., Marr K.A., Lau W.M., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53 (2006) 337-349
115. Marr K.A., Boeckh M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802
116. Raad I.I., Hanna H.A., Boktour M., et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leucemia 22 (2008) 496-503
117. Liles W.C., Huang J.E., van Burik J.A., Bowden R.A., and Dale D.C. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 175 (1997) 1012-1015
118. Böhme A., Ruhnke M., Buchheidt D., et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 88 (2009) 97-110
119. Thursky K.A., Playford E.G., Seymour J.F., et al. Recommendations for the treatment of established fungal infections. Intern Med J 38 (2008) 496-520
120. Pagano L., Ricci P., Tonso A., et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA infection. Br J Haematol 99 (1997) 331-336
121. Chamilos G., Lewis R.E., and Kontoyiannis D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47 (2008) 503-509
122. Greenberg R.N., Mullane K., van Burik J.A., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50 (2006) 126-133
123. van Burik J.A., Hare R.S., Solomon H.F., Corrado M.L., and Kontoyiannis D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42 (2006) e61-e65
124. Reed C., Bryant R., Ibrahim A.S., et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 47 (2008) 364-371
125. John B.V., Chamilos G., and Kontoyiannis D.P. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 11 (2005) 515-517
126. Spellberg B, Bonilla H, Perez M, et al. Safety and outcomes of Deferasirox Iron Chelation therapy for Mucormycosis. 48th ICAAC/IDSA, 203, 676, 2008, (Abstract M-2175).
127. Troke P., Aguirrebengoa K., Arteaga C., et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 52 (2008) 1743-1750
128. Nucci M., Anaissie E.J., Queiroz-Telles F., et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98 (2003) 315-319